VIR BIOTECHNOLOGY INC (VIR) Stock Price, Quote, News and Overview
NASDAQ:VIR - Nasdaq - US92764N1028 - Common Stock - Currency: USD
VIR Quote, Performance and Key Statistics
5.61
+0.11 (+2%)
The current stock price of VIR is 5.61 USD. In the past month the price decreased by -19.05%. In the past year, price decreased by -31.83%.
VIR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.81 | 301.01B | ||
| AMGN | AMGEN INC | 13.81 | 147.14B | ||
| GILD | GILEAD SCIENCES INC | 22.63 | 130.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1646.62 | 122.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.3 | 61.38B | ||
| ARGX | ARGENX SE - ADR | 320.27 | 36.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.28B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.70B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.47B | ||
| NTRA | NATERA INC | N/A | 19.23B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.60B | ||
| BIIB | BIOGEN INC | 7.07 | 17.05B |
Related stock screener links
About VIR
Company Profile
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 408 full-time employees. The company went IPO on 2019-10-11. The firm's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The firm's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. The company also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Company Info
VIR BIOTECHNOLOGY INC
1800 Owens Street, Suite 900
San Francisco CALIFORNIA 94158 US
CEO: George Scangos
Employees: 587
Company Website: https://www.vir.bio/
Investor Relations: https://investors.vir.bio/
Phone: 14159064324
VIR BIOTECHNOLOGY INC / VIR FAQ
What is the stock price of VIR BIOTECHNOLOGY INC today?
The current stock price of VIR is 5.61 USD. The price increased by 2% in the last trading session.
What is the ticker symbol for VIR BIOTECHNOLOGY INC stock?
The exchange symbol of VIR BIOTECHNOLOGY INC is VIR and it is listed on the Nasdaq exchange.
On which exchange is VIR stock listed?
VIR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VIR BIOTECHNOLOGY INC stock?
13 analysts have analysed VIR and the average price target is 35.26 USD. This implies a price increase of 528.57% is expected in the next year compared to the current price of 5.61. Check the VIR BIOTECHNOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VIR BIOTECHNOLOGY INC worth?
VIR BIOTECHNOLOGY INC (VIR) has a market capitalization of 769.36M USD. This makes VIR a Small Cap stock.
How many employees does VIR BIOTECHNOLOGY INC have?
VIR BIOTECHNOLOGY INC (VIR) currently has 587 employees.
What are the support and resistance levels for VIR BIOTECHNOLOGY INC (VIR) stock?
VIR BIOTECHNOLOGY INC (VIR) has a resistance level at 5.73. Check the full technical report for a detailed analysis of VIR support and resistance levels.
Is VIR BIOTECHNOLOGY INC (VIR) expected to grow?
The Revenue of VIR BIOTECHNOLOGY INC (VIR) is expected to decline by -60.63% in the next year. Check the estimates tab for more information on the VIR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VIR BIOTECHNOLOGY INC (VIR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VIR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VIR, evaluating the profitability, health, valuation and growth aspects
- VIR BIOTECHNOLOGY INC (VIR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VIR BIOTECHNOLOGY INC (VIR) Sales and EPS estimates to see what analysts future expectations are.
- VIR BIOTECHNOLOGY INC (VIR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VIR BIOTECHNOLOGY INC (VIR) Insider and Institutional Ownership to learn about the owners and their transactions.
- VIR BIOTECHNOLOGY INC (VIR) Stock Chart to make your own analysis
- VIR BIOTECHNOLOGY INC (VIR) Latest news and press-releases to stay up to date.
Does VIR BIOTECHNOLOGY INC (VIR) stock pay dividends?
VIR does not pay a dividend.
When does VIR BIOTECHNOLOGY INC (VIR) report earnings?
VIR BIOTECHNOLOGY INC (VIR) will report earnings on 2025-05-01, after the market close.
What is the Price/Earnings (PE) ratio of VIR BIOTECHNOLOGY INC (VIR)?
VIR BIOTECHNOLOGY INC (VIR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.82).
What is the Short Interest ratio of VIR BIOTECHNOLOGY INC (VIR) stock?
The outstanding short interest for VIR BIOTECHNOLOGY INC (VIR) is 7.71% of its float. Check the ownership tab for more information on the VIR short interest.
VIR Technical Analysis
VIR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to VIR. No worries on liquidiy or solvency for VIR as it has an excellent financial health rating, but there are worries on the profitability.
VIR Financial Highlights
Over the last trailing twelve months VIR reported a non-GAAP Earnings per Share(EPS) of -3.82. The EPS increased by 16.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.31% | ||
| ROE | -45.37% | ||
| Debt/Equity | 0 |
VIR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to VIR. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 11.1% and a revenue growth -60.63% for VIR